-
公开(公告)号:US11932633B2
公开(公告)日:2024-03-19
申请号:US17053273
申请日:2019-05-06
Applicant: Mirati Therapeutics, Inc. , Array BioPharma, Inc.
Inventor: Matthew Arnold Marx , Matthew Randolph Lee , James F. Blake , Mark Joseph Chicarelli , Jay Bradford Fell , John P. Fischer , Erik James Hicken , Pavel Savechenkov , Tony Tang , Guy P. A. Vigers , Henry J. Zecca
IPC: C07D413/06 , A61P35/00 , C07D413/04 , C07D413/14 , C07D417/14
CPC classification number: C07D413/14 , A61P35/00 , C07D413/06
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号:US20210380570A1
公开(公告)日:2021-12-09
申请号:US17053273
申请日:2019-05-06
Applicant: Mirati Therapeutics, Inc. , Array BioPharma, Inc.
Inventor: Matthew Arnold Marx , Matthew Randolph Lee , James F. Blake , Mark Joseph Chicarelli , Jay Bradford Fell , John P. Fischer , Erik James Hicken , Pavel Savechenkov , Tony Tang , Guy P.A. Vigers , Henry J. Zecca
IPC: C07D413/14 , C07D413/06 , A61P35/00
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号:US20210230170A1
公开(公告)日:2021-07-29
申请号:US17272276
申请日:2019-08-29
Applicant: Mirati Therapeutics, Inc. , Array BioPharma, Inc.
Inventor: Matthew Arnold Marx , James F. Blake , Jay Bradford Fell , John P. Fischer , Macedonio J. Mejia
IPC: C07D487/04 , A61P35/00
Abstract: The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号:US20190177328A1
公开(公告)日:2019-06-13
申请号:US16212493
申请日:2018-12-06
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor: Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: C07D487/04 , A61K45/06 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
公开(公告)号:US10189845B2
公开(公告)日:2019-01-29
申请号:US15532937
申请日:2015-12-04
Applicant: ARRAY BIOPHARMA INC. , CELGENE CORPORATION
Inventor: Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
公开(公告)号:US20180072723A1
公开(公告)日:2018-03-15
申请号:US15814279
申请日:2017-11-15
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor: James F. Blake , Laurence E. Burgess , Mark Joseph Chicarelli , James Gail Christensen , Jay Bradford Fell , John P. Fischer , John J. Gaudino , Erik James Hicken , Ronald Jay Hinklin , Matthew Randolf Lee , Matthew Arnold Marx , Macedonio J. Mejia , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P.A. Vigers , Henry J. Zecca
IPC: C07D471/04
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号:US20230279025A1
公开(公告)日:2023-09-07
申请号:US18015691
申请日:2021-02-25
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor: Xiaolun Wang , Aaron Craig Burns , James Gail Christensen , John Michael Ketcham , John David Lawson , Matthew Arnold Marx , Christopher Ronald Smith , Shelley Allen , James Francis Blake , Mark Joseph Chicarelli , Joshua Ryan Dahlke , Donghua Dai , Jay Bradford Fell , John Peter Fischer , Macedonio J. Mejia , Brad Newhouse , Phong Nguyen , Jacob Matthew O'Leary , Spencer Pajk , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P.A. Vigers , Qian Zhao , Dean Russell Kahn , John Gaudino , Michael Christopher Hilton
IPC: C07D519/00
CPC classification number: C07D519/00 , C07B2200/05
Abstract: The present invention relates to compounds that inhibit KRas G12D, In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号:US11453683B1
公开(公告)日:2022-09-27
申请号:US17005004
申请日:2020-08-27
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor: Xiaolun Wang , Aaron Craig Burns , James Gail Christensen , John Michael Ketcham , John David Lawson , Matthew Arnold Marx , Christopher Ronald Smith , Shelley Allen , James F. Blake , Mark Joseph Chicarelli , Joshua Ryan Dahlke , Donghua Dai , Jay Bradford Fell , John Peter Fischer , Macedonio J. Mejia , Brad Newhouse , Phong Nguyen , Jacob Matthew O'Leary , Spencer Pajk , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P. A. Vigers , Qian Zhao , Dean Russell Kahn , John Gaudino , Michael Christopher Hilton
IPC: C07D519/00
Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:US11267812B2
公开(公告)日:2022-03-08
申请号:US16099398
申请日:2017-05-17
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor: John P. Fischer , Jay Bradford Fell , James F. Blake , Ronald Jay Hinklin , Macedonio J. Mejia , Erik James Hicken , Mark Joseph Chicarelli , John J. Gaudino , Guy P. A. Vigers , Laurence E. Burgess , Matthew Arnold Marx , James Gail Christensen , Matthew Randolph Lee , Pavel Savechenkov , Henry J. Zecca , Tony P. Tang
IPC: C07D471/04 , C07D519/00 , A61P35/00
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号:US20190062330A1
公开(公告)日:2019-02-28
申请号:US16173726
申请日:2018-10-29
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor: James F. Blake , Laurence E. Burgess , Mark Joseph Chicarelli , James Gail Christensen , Jay Bradford Fell , John P. Fischer , John J. Gaudino , Erik James Hicken , Ronald Jay Hinklin , Matthew Randolf Lee , Matthew Arnold Marx , Macedonio J. Mejia , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P.A. Vigers , Henry J. Zecca
IPC: C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
-
-
-
-
-
-
-
-